Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluation.
Gene panels
Hereditary cancer
Multidisciplinary care
Next generation sequencing
Secondary findings
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
29
04
2021
revised:
04
02
2022
accepted:
16
02
2022
pubmed:
9
3
2022
medline:
27
7
2022
entrez:
8
3
2022
Statut:
ppublish
Résumé
Current methods of next generation sequencing may simultaneously detect multiple germline breast cancer susceptibility variants. However, it is a challenge to maximize the clinical benefit of genetic analysis for patients and family members while minimizing potentially harmful effects. Relevant issues include criteria for referral, the choice of gene panel, handling of variants of unknown significance, cancer risk counselling in clinical context including family history data, risks of tumours other than breast cancer, handling of potential germline findings revealed by tumour testing and the clinical management of gene variant carriers, including surveillance, targeted therapy, radiotherapy and risk-reducing surgery. We outline current challenges in the field of breast cancer genetics and call for novel forms of multidisciplinary care and long-term evaluation.
Identifiants
pubmed: 35257886
pii: S1040-8428(22)00066-X
doi: 10.1016/j.critrevonc.2022.103642
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103642Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.